After only two doses, nearly eight out of ten participants in a phase 2 trial by Toronto-based pharmaceutical company Cybin experienced remission from major depressive disorder at six weeks. The company has a planned phase 3 study slated to commence by the end of Q1 2024.
Initially, a Ford E-Transit fitted with a receiver will be used to gather data as part of a five-year pilot to perfect the technology in real-world settings and study potential public transport applications – though there are plans to open the electric road system to the public within the next few years.
Green ammonia offers a solution to one of the hardest tasks in decarbonization: replacing diesel in large ships. Yara is stepping forward with a commitment to launch the world’s first clean ammonia-powered container ship, ready for service in 2026. Shipping is responsible for between 1.7 and 3% of global CO2 emissions.
SAF is designed to cut aviation carbon emissions by using sources that rely much less on fossil fuels: include maize, seed oils, algae, animal fats, oils, greases, farm residues, and more. According to Gulfstream, SAF has the potential to reduce net carbon emissions by 70%.
Besides the eyeball, the patient, 46-year-old Aaron James of Hot Springs, Arkansas, also received a partial face transplant and an infusion of donor stem cells to the optic nerve during the more than 20-hour surgery.
The Dominique barge is designed to provide a net output of 1.5 megawatts year-round, enough to supply nearly 17% of the nation’s entire 78 million-odd kilowatt hour energy consumption. London company Global OTEC plans to begin commissioning the project in 2023.
Researchers from the Cleveland Clinic have conducted the first human trials of a new drug, lepodisiran, that has the potential to eliminate a risk factor for cardiovascular disease for which there is currently no treatment.
The scientists from Shanghai’s Fudan University implanted new genetic code into a harmless virus and then injected the viruses into the children’s cochlea. They say the experiment has sparked hearing in four out of five children who received the treatment.
Dubbed “Calixcoca,” the treatment, developed by researchers at the Federal University of Minas Gerais, triggers an immune response that blocks cocaine and crack from reaching the brain. Last week, the project won the top prize of €500,000 at the Euro Health Innovation Awards for Latin American medicine.
The researchers from the University of Cambridge found that, on its own, the blood test could diagnose up to 30% of patients with BD, but combining it with the online psychiatric assessment significantly improved the diagnosis rate, especially in people whose diagnosis was not obvious.
